Welcome to our dedicated page for Savara news (Ticker: SVRA), a resource for investors and traders seeking the latest updates and insights on Savara stock.
Savara Inc. (Nasdaq: SVRA) is a clinical stage biopharmaceutical company focused on rare respiratory diseases, with its lead program MOLBREEVI in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The Savara news feed highlights regulatory, clinical, financial, and corporate developments that shape the company’s progress toward potential approval and commercialization of its investigational therapy.
News items commonly include updates on the Biologics License Application (BLA)
Investors and observers can follow announcements on intellectual property, including European Patent Office decisions related to the liquid formulation of MOLBREEVI and the drug–device combination with the proprietary investigational eFlow® Nebulizer System. Additional news covers capital markets activity, such as underwritten public offerings of common stock and pre-funded warrants, as well as a royalty funding agreement tied to potential future U.S. net sales of MOLBREEVI.
The news stream also features corporate and partnering updates, including Savara’s selection of PANTHERx Rare Pharmacy as the exclusive U.S. specialty pharmacy for MOLBREEVI, and participation in major healthcare and investor conferences. For those tracking SVRA, this page provides a centralized view of Savara’s public announcements related to clinical data presentations, regulatory interactions, financing events, and commercialization planning for its rare respiratory disease program.
Savara (Nasdaq: SVRA) announced inducement equity awards granted January 15, 2026 to two newly hired employees under the Savara 2021 Inducement Equity Incentive Plan pursuant to NASDAQ Rule 5635(c)(4). The awards total 17,500 stock options and 12,500 restricted stock units (RSUs). Options carry an exercise price of $5.88 (closing price on the grant date), a 10-year term, and vest at 1/16th per quarterly anniversary of the employee’s first day of employment. The RSUs vest in full after two years subject to continued employment. The grants were described as inducements material to the employees’ acceptance of employment.
Savara (NASDAQ: SVRA) announced an exclusive U.S. distribution agreement with PANTHERx Rare Pharmacy for MOLBREEVI. Savara submitted the MOLBREEVI BLA to the FDA in December 2025 and requested Priority Review. If approved, PANTHERx will dispense MOLBREEVI nationwide using its RxARECARE model and the eFlow® Nebulizer System, offering clinical case management, education, and financial and insurance assistance. PANTHERx reported 95.45% of its patients have no unresolved barriers at annual assessment.
Savara (Nasdaq: SVRA) announced it resubmitted the MOLBREEVI Biologics License Application to the U.S. FDA on December 22, 2025, naming Fujifilm as the drug substance manufacturer and requesting Priority Review.
MOLBREEVI seeks approval for the treatment of autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The program previously received Fast Track and Breakthrough Therapy designations from FDA, Orphan Drug designation from FDA and EMA, and Innovation Passport (IP) and Promising Innovative Medicine (PIM) designations from the UK MHRA.
Savara (Nasdaq: SVRA) said members of management will present and host one-on-one meetings at the 44th Annual J.P. Morgan Healthcare Conference.
Presentation: Wednesday, January 14, 2026 at 5:15 PM PT / 8:15 PM ET; Presenter: Matt Pauls, Chair and Chief Executive Officer.
Location: Westin St. Francis, San Francisco, Elizabethan B Room. A live webcast and replay will be available on the company’s Events & Presentations page and will be archived for 30 days.
Savara (Nasdaq: SVRA) said the European Patent Office intends to grant a patent for the liquid formulation of MOLBREEVI, which would provide protection in Europe through March 2041. The company also noted a separate European patent already granted for the drug-device combination of MOLBREEVI delivered via PARI’s eFlow® nebulizer, covering protection through March 2043.
Savara said MOLBREEVI would be eligible for 10 years of Orphan Drug exclusivity in the EU upon approval. The company expects to resubmit the MOLBREEVI BLA to the FDA in December 2025 and to file MAA submissions in the EU and U.K. by the end of 1Q 2026. MOLBREEVI holds FDA Fast Track and Breakthrough Therapy designations, FDA and EMA Orphan Drug designations, and MHRA IP and PIM designations for autoimmune PAP.
Savara (Nasdaq: SVRA) and PARI were granted European Patent No. 4 496 611 covering the drug-device combination of MOLBREEVI delivered via the eFlow® Nebulizer System.
The patent covers the combination through March 2043. The company cited a 10-year Orphan Drug regulatory exclusivity upon EU approval and noted an exclusive license with PARI. Savara plans a December resubmission of the MOLBREEVI BLA in the U.S. and 1Q 2026 MAA submissions in Europe and the U.K. Regulatory designations include FDA Fast Track, Breakthrough Therapy, FDA and EMA Orphan Drug, and the UK’s Innovation Passport and PIM designations. The eFlow system is planned for commercial launch as the Vespera Nebulizer System if approved.
Savara (Nasdaq: SVRA) said members of its management team will hold one-on-one meetings and take part in fireside chats at two investor healthcare conferences in early December 2025.
Fireside chat schedule: Piper Sandler 37th Annual Healthcare Conference on Dec 2, 2025 at 2:30pm ET and Evercore ISI 8th Annual Healthcare Conference on Dec 4, 2025 at 10:00am ET. Live webcasts and replays will be available in the company’s Events & Presentations section and archived for 90 days.
Savara (NASDAQ: SVRA) reported third quarter 2025 results and a business update on November 12, 2025. The company said it is on track to resubmit the MOLBREEVI BLA for autoimmune pulmonary alveolar proteinosis in December 2025 and will request priority review. Savara expects to submit Marketing Authorization Applications to the EMA and MHRA in 1Q 2026. Recent financings strengthened the balance sheet: a public equity offering that added ~$140M and a ~$75M royalty funding agreement; cash, cash equivalents and short-term investments were ~$124.4M as of September 30, 2025. Q3 net loss was $29.6M (loss per share $(0.14)); research and development and commercial preparations continued.
Savara (Nasdaq: SVRA) said members of its management team will host 1x1 meetings and participate in fireside chats at two upcoming healthcare conferences.
Fireside chats: Guggenheim 2nd Annual Healthcare Innovation Conference on November 10, 2025 at 8:30 a.m. ET, and Jefferies London Healthcare Conference on November 19, 2025 at 12:00 p.m. GMT. Live webcasts and replays will be available in the company’s Events & Presentations section and will be archived for 90 days.
Savara (NASDAQ:SVRA) announced the closing of its underwritten public offering on October 31, 2025, raising approximately $149.5 million in gross proceeds before fees. The offering included 28,452,381 shares of common stock sold at $4.20 per share, which reflects the full exercise by the underwriters of their option to purchase 4,642,857 additional shares. In lieu of shares, certain investors bought 7,142,857 pre-funded warrants at $4.199 each. The securities were offered under Savara's shelf registration (File No. 333-279274); the final prospectus supplement was filed on October 30, 2025.
FAQ
What is the current stock price of Savara (SVRA)?
What is the market cap of Savara (SVRA)?
